[195+ Pages Research Report] According to Facts and Factors market research report, the Global C1 Inhibitors Market size & share revenue is expected to grow from USD 3,300 Million in 2019 to reach USD 9,800 Million by 2026, at 18.6% annual CAGR growth during forecast period of 2021-2026. The top market companies profiles included in report with their sales, revenues and strategies are Viropharma Biologics, Inc., Ionis Pharmaceuticals, Inc., iBio, Inc., Sanquin, and BioCryst Pharmaceuticals and others.

New York, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous), By End-User (Hospitals & Pharmacies), and By Regions - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026”.

“According to the recent research report, the demand of global C1 Inhibitors Market size & share expected to reach to USD 9,800 Million by 2026 from USD 3,300 Million in 2019, at a compound annual growth rate (CAGR) of 18.6% during the forecast period 2021 to 2026”

Global C1 Inhibitors Market: Overview

C1 inhibitors are a type of protease inhibitor that belongs to a protein-based ingredient called serpin. They are also called C1 esterase inhibitors; however, unlike other members of the protein tree, they contain both the domains C-terminal and N-terminal. These inhibitors basically help lower the self-consciousness of the complement system to prevent any type of damage as well as to retain the functionality. It is an FXIIa inhibitor that can help coagulate blood, produce kinins or fibrinolysis, and also activate the complement system.

The rising prevalence of hereditary angioedema (HAE) diseases and the preferred mode of treatment for prophylactic-based disorders are likely to drive the growth of the market during the forecast period. Additionally, certain impactful studies have indicated that the use of C1 inhibitors will further drive the growth of the market. Furthermore, the growing awareness regarding the effectiveness of C1 inhibitors and their ability in preventing heart attacks will boost the market expansion. C1 inhibitors use as a short-term treatment for prophylactic diseases propel the demand for this product across the globe. But, a few of the reasons including misdiagnosis, expensive medicines, and longer time for reimbursements are projected to restrain the market growth.

Request Your Free Sample Report of Global C1 Inhibitors Market @ https://www.fnfresearch.com/sample/c1-inhibitors-market   

(The free sample of this report is readily available on request).

Our Free Sample Report Includes:

• 2020 Updated Report Introduction, Overview, and In-depth industry analysis
• COVID-19 Pandemic Outbreak Impact Analysis Included
• 195+ Pages Research Report (Inclusion of Updated Research)
• Provide Chapter-wise guidance on Request
• 2020 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
• Includes Updated List of table & figures
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
• Facts and Factors research methodology

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Industry Major Market Players

• Shire
• CSL Behring
• Lev Pharmaceuticals
• Pharming Group
• Salix Pharmaceuticals
• Viropharma Biologics Inc.
• Ionis Pharmaceuticals Inc.
• iBio Inc.
• Sanquin
• BioCryst Pharmaceuticals

To know an additional revised list of 2020-2021 top market players, request a sample report: https://www.fnfresearch.com/sample/c1-inhibitors-market         

Key questions answered in this report:

• What is the projected market size & growth rate of the C1 Inhibitors Market?
• What are the key driving factors for the growth of the C1 Inhibitors Market?
• What are the top companies operative in C1 Inhibitors Market?
• What segments are covered in C1 Inhibitors Market?
• How can I get free sample report/company profiles of the C1 Inhibitors Market?

Market Dynamics

The C1 inhibitor market can be divided into human-derived and recombinantly derived on the basis of the source. The human-derived C1 inhibitor segment can be further broken down into CINRYZE, Berinert, and HAEGARDA while the recombinant derived segment can be further broken down into Ruconest

The C1 inhibitors market can be broken down into intravenous and subcutaneous on the basis of mode of administration. Growing adoption of the subcutaneous route of administration by doctors and improving availability of Ruconest further fuel the C1 inhibitor market. Thus, the subcutaneous mode of administration is likely to exhibit maximum market revenue.

Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/c1-inhibitors-market

Global C1 Inhibitors Market: Growth Factors

High growth in the rise of hereditary angioedema (HAE) and the preferred use of prophylactic treatment will drive the market to higher growth. Additionally, benefits include treatment and prevention of acute attacks and routine prophylaxis against other forms of HAE. Other drivers for the C1 inhibitors market include a rise in awareness by various studies that show the effective nature of C1 inhibitors in the treatment of HAE diseases.

The rising requirement for the treatment of HAE diseases coupled with the growing awareness regarding these diseases is all projected to drive the global C1 inhibitors market growth. Growing investments also fuel the market. The rising occurrence of HAE increases the demand for C1 inhibitors, thereby boosting the market during the forecast period.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/c1-inhibitors-market

(We customize your report according to your research need. Ask our sales team for report customization.)

North America Is Expected To Flourish During the Forecast Period

North America is expected to recoup the largest market share during the forecast period in terms of global revenue collection. Factors pertaining to the rise of the market in the region can be contributed to increased awareness about HAE treatment protocols and widened support for reimbursement support from governmental agencies. Additionally, the well-established healthcare infrastructure and improved healthcare access will also help boost the global C1 inhibitors market in this region.

Browse the full “C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous), By End-User (Hospitals & Pharmacies), and By Regions - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026” report at https://www.fnfresearch.com/c1-inhibitors-market

The global C1 Inhibitors Market can be segmented into:

Global C1 Inhibitors Market: By Source Segment Analysis

• Human Derived C1 Inhibitors
  • CINRYZE
  • Berinert
  • HAEGARDA
• Recombinant Derived C1 Inhibitors
  • Ruconest

Global C1 Inhibitors Market: By Mode of Administration Segment Analysis

• Intravenous
• Subcutaneous

Global C1 Inhibitors Market: By End-User Segment  Analysis

• Hospitals
• Pharmacies

Key Highlights of this Report:

• Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable
• Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications
• Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market
• Market Attractiveness Analysis and Key Investment Opportunity Analysis in the Market going forward
• Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward
• Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data

For media inquiry, mail to: sales@fnfresearch.com

About Facts & Factors (FnF Research):

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearch

Follow Us Twitter: https://twitter.com/fnfresearch

Contact Us:

Facts & Factors

USA: +1-347-989-3985

Email: sales@fnfresearch.com

Web: https://www.fnfresearch.com

Blog: http://fnfnewsblog.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.